Stocks Health care ELAN
NYSE · Health careElanco Animal Health Inc (ELAN)
Elanco Animal Health Inc brought in $5.1B of revenue over the twelve months to September 30, 2026, up 12.1% from a year earlier. It posted a net loss of $147M. Operating cash flow minus capital spending left $284M of free cash flow in fiscal 2025. At September 30, 2026 it held $465M in cash against $3.4B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 6, 2026.
Key facts about Elanco Animal Health Inc
- Net worth
- Elanco Animal Health Inc has a market value (market cap) of $13.4B at the latest share price, and shareholders' equity of $6.6B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $4.7B (+6.2% year on year), with a net loss of $232M. Over the 12 months to September 30, 2026: revenue $5.1B, net loss $147M.
- Cash flow
- In fiscal 2025 operations brought in $560M of cash; after $276M of capital spending, free cash flow was $284M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 6, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Elanco Animal Health Inc's next report is expected around February 23, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Elanco Animal Health Inc does
Elanco Animal Health Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker ELAN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $4.7B | -$232M | -$0.47 | $284M |
| 2024 | $4.4B | $338M | $0.68 | $394M |
| 2023 | $4.4B | -$1.2B | -$2.50 | $131M |
| 2022 | $4.4B | -$78M | -$0.16 | $281M |
| 2021 | $4.8B | -$483M | -$0.99 | $324M |
| 2020 | $3.3B | -$574M | -$1.30 | -$176M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where ELAN ranks in Health care
Latest SEC filings
What Elanco Animal Health Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 6, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 11% to $1.3B versus the same quarter last year; diluted EPS $0.04 versus -$0.07.
- November 6, 2026
- November 5, 2026Passive stake changed SCHEDULE 13G/A
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 10% to $1.4B versus the same quarter last year; diluted EPS $0.11 versus $0.02.
- August 5, 2026
- July 14, 2026Passive stake (5% or more) SCHEDULE 13G
- May 27, 2026
- May 27, 2026
- May 14, 2026Passive stake changed SCHEDULE 13G/A
- May 13, 2026Passive stake changed SCHEDULE 13G/A
What is ELAN worth? A DCF from its reported cash flow
Insider trades
What the people running Elanco Animal Health Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $1M and sold $100.1K worth of shares in the last 90 days. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 15, 2026 | Bettington Timothy JSEE REMARKS | Soldpre-planned (10b5-1) | 4,350 | $100.1K |
| August 20, 2026 | Kurzius Lawrence ErikDirector | Bought | 40,000 | $935.9K |
| August 18, 2026 | O'Neill ShivGC AND CORP SEC | Bought | 3,998 | $94.3K |
| August 12, 2026 | Harrington Michael JDirector | Bought | 5,000 | $109.1K |
| August 7, 2026 | Herendeen PaulDirector | Bought | 10,000 | $236.9K |
| August 7, 2026 | VanHimbergen Robert MEVP and CFO | Bought | 4,200 | $96.9K |
| July 7, 2026 | VanHimbergen Robert MEVP and CFO | Shares withheld for tax | 15,336 | $377.9K |
| May 21, 2026 | Garcia Art ADirector | Received as pay | 4,678 | - |
Who owns ELAN
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Dodge & Cox13G, passive | 13.9% | May 14, 2026 |
| Fmr LLC13G, passive with 1 related filers | 10.5% | February 5, 2026 |
| Primecap Management Co13G, passive | 9.22% | May 13, 2026 |
| T. Rowe Price Investment Management, Inc.13G, passive | 6.4% | November 14, 2025 |
| Vanguard Capital Management13G, passive | 5.25% | April 29, 2026 |
| Dimensional Fund Advisors LP13G, passive | 5.1% | July 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 520 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Dodge & Cox | 67,397,025 | -1,547,075 |
| Fmr LLC | 56,948,819 | +6,023,453 |
| BlackRock, Inc. | 48,849,973 | +1,227,343 |
| Primecap Management Co | 45,445,012 | -395,944 |
| Dimensional Fund Advisors LP | 25,417,271 | +890,136 |
| Vanguard Portfolio Management LLC | 22,672,312 | +34,955 |
| Vanguard Capital Management LLC | 22,607,532 | +271,408 |
| State Street Corp | 16,063,046 | +726,567 |
| Winslow Capital Management, LLC | 13,511,127 | -103,228 |
| Black Creek Investment Management Inc. | 13,046,420 | +2,552,571 |
| Geode Capital Management, LLC | 11,302,057 | +109,653 |
| UBS Group AG | 9,910,822 | +1,338,765 |
| Citadel Advisors LLC | 9,668,611 | +5,281,484 |
| Manufacturers Life Insurance Company, The | 8,355,772 | +2,126,727 |
| Morgan Stanley | 7,854,362 | +1,436,835 |
| Fuller & Thaler Asset Management, Inc. | 6,240,240 | +225,176 |
| Invesco Ltd. | 5,306,326 | -2,834,846 |
| Sei Investments Co | 5,284,773 | -365,620 |
| Jennison Associates LLC | 4,508,395 | +1,387,730 |
| Marshall Wace, Llp | 4,432,350 | +3,049,938 |
Insiders
21 insiders reported holding 5,047,883 shares in total, about $135.5M at the last price.
| Holder | Shares |
|---|---|
| Simmons Jeffrey NPRESIDENT, CEO AND DIRECTOR, Director | 2,223,869171,971 held indirectly |
| Cabral Ramiro MartinSEE REMARKS | 283,874 |
| de Brabander EllenSEE REMARKS | 280,821 |
| Hoover R DavidDirector | 261,451150,000 held indirectly |
| Kinard David SSEE REMARKS | 214,264 |
| Kurzius Lawrence ErikDirector | 188,647 |
| Modi Rajeev A.SEE REMARKS | 160,812 |
| Bettington Timothy JSEE REMARKS | 138,911 |
| VanHimbergen Robert MEVP and CFO | 137,516 |
| Harrington Michael JDirector | 131,451 |
Questions about ELAN
What does Elanco Animal Health Inc do?
Elanco Animal Health Inc is a company in the Health care sector, listed on NYSE as ELAN. Its shares trade on NYSE under the ticker ELAN.
What is Elanco Animal Health Inc's net worth?
Elanco Animal Health Inc has a market value (market cap) of $13.4B at the latest share price, and shareholders' equity of $6.6B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Elanco Animal Health Inc profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $147M on revenue of $5.1B.
How much revenue does Elanco Animal Health Inc make?
Over the twelve months to September 30, 2026 Elanco Animal Health Inc reported revenue of $5.1B. That is 12.1% more than a year earlier.
When did Elanco Animal Health Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 6, 2026. It covers the period to September 30, 2026.
When is Elanco Animal Health Inc's next earnings report?
Elanco Animal Health Inc's next report is expected around February 23, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ELAN with
Follow ELAN
Get an email when Elanco Animal Health Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Elanco Animal Health Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.